⚙
AI-generated deep summary
by qwen3.7-flash, 2026-09-08
· read from full text
ⓘ
This study evaluated the efficacy of danazol in treating chronic refractory immune thrombocytopenic purpura (ITP) among 50 patients who had failed corticosteroid and other immunosuppressive therapies. The researchers administered danazol at doses ranging from 200 to 600 mg daily for twelve weeks, monitoring platelet counts and bleeding manifestations at regular intervals. Results indicated a high initial response rate of 79.2% by day seven, with sustained complete or partial remission observed in a majority of participants by the end of the treatment period. This paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.
Abstract
50 patients of chronic ITP were registered in Hematology Department, BSMMU, Dhaka. During this study period (1 yr.) among 50 patients 30 (60 %) were female & 20 (40%) were male. 56% patients were belong to 21- 40 yrs & 32% were between 15- 20 yrs. In this study 50 patients were selected who are refractory to corticosteroid, azathioprine, and cyclophosphamide but none were splenectomized. Patients were above 15 yrs. and have long history of ITP (2 yrs). Out of 50, 48 patients treated with danazol for 12 wks (200- 600mg/day). Patients were followed up on day 7 & 4 wkly up to 12 wks for platelet count, bleeding manifestation & toxicities. Treatment was started to 50 selected patient but 2 patients discontinued the therapy after first dose and remaining 48 patients were completed the therapy. After starting of danazol on day 7, response rate was 79.2% (platelet count raised in 38 patients out of 48 ).On 4th week follow up, 25% (12 patients) achieved (CR) complete remission ( platelet count ≥ 1,50,000/cmm), 62.5% (30 patients) achieved (PR) partial remission( platelet count ≥ 50,000- <1,50,000/cmm) and 6 had no response at all. On 8th week, 7 patients remained in CR (14.6%), 5 in relapsed remained in partial remission. 14.5% (7) patients remained in CR, 10.4% (5) in relapsed remained in partial remission on 12th week. Overall result out of 50 patients (2 excluded who were not attended for follow up & 6 were not responded at all) CR 14.5% (7 patients), PR 72.9% (35 patients).It is cleared from this study & supported by other studies that danazol promptly raised platelets count within 5-10 days with excellent response (79.2%). DOI: 10.3329/taj.v22i1.5026 TAJ 2009; 22(1): 93-96
Full text
1,788 characters
· extracted from
oa-doi-fallback
· click to expand
Treatment of Chronic Refractory ITP with Danazol
Keywords:
Refractory ITPAbstract
50 patients of chronic ITP were registered in Hematology Department, BSMMU, Dhaka. During this study period (1 yr.) among 50 patients 30 (60 %) were female & 20 (40%) were male. 56% patients were belong to 21- 40 yrs & 32% were between 15- 20 yrs. In this study 50 patients were selected who are refractory to corticosteroid, azathioprine, and cyclophosphamide but none were splenectomized. Patients were above 15 yrs. and have long history of ITP (2 yrs). Out of 50, 48 patients treated with danazol for 12 wks (200- 600mg/day). Patients were followed up on day 7 & 4 wkly up to 12 wks for platelet count, bleeding manifestation & toxicities. Treatment was started to 50 selected patient but 2 patients discontinued the therapy after first dose and remaining 48 patients were completed the therapy. After starting of danazol on day 7, response rate was 79.2% (platelet count raised in 38 patients out of 48 ).On 4th week follow up, 25% (12 patients) achieved (CR) complete remission ( platelet count ≥ 1,50,000/cmm), 62.5% (30 patients) achieved (PR) partial remission( platelet count ≥ 50,000- <1,50,000/cmm) and 6 had no response at all. On 8th week, 7 patients remained in CR (14.6%), 5 in relapsed remained in partial remission. 14.5% (7) patients remained in CR, 10.4% (5) in relapsed remained in partial remission on 12th week. Overall result out of 50 patients (2 excluded who were not attended for follow up & 6 were not responded at all) CR 14.5% (7 patients), PR 72.9% (35 patients).It is cleared from this study & supported by other studies that danazol promptly raised platelets count within 5-10 days with excellent response (79.2%).
DOI: 10.3329/taj.v22i1.5026
TAJ 2009; 22(1): 93-96
513
250
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.